CPAY vs FISV

• CPAYBuy moresales growth, past year21%

  Corpay's sales grew 21% over the past year, and the stock rose 10% over the past five trading days after its Nov 4 report beat profit forecasts by 6.1%.

• FISVBuy morein the past month+40%

  Fiserv rose 40% over the past month, far more than other financial stocks (up 6%).

Percent return

• CPAY+58.93%
• FISV−0.56%

1M6MYTD1Y5YMax

Nov 11, 2025 to Nov 11, 2026

Where they differ

CPAY leads on 5 of 6

CPAYFISV

• Company size: CPAY $25.7B, FISV $29.7B.
  $25.7BCompany sizebigger$29.7B
• Sales growth, 1 yr: CPAY +21%, FISV −1.7%. CPAY is ahead.
  +21%Sales growth, 1 yr−1.7%
• Price for $1 of next year's profit: CPAY $15, FISV $8. FISV is ahead.
  $15Price for $1 of next year's profitcheaper$8
• Profit per $1 of sales: CPAY 50¢, FISV 19¢. CPAY is ahead.
  50¢Profit per $1 of sales19¢
• Cash minus debt: CPAY −$8.26B, FISV −$26.7B. CPAY is ahead.
  −$8.26BCash minus debt−$26.7B
• Price change, 1 yr: CPAY +59%, FISV −0.6%. CPAY is ahead. S&P 500 +12%.
  +59%Price change, 1 yr−0.6%
• How much the price swings: CPAY 26%, FISV 42%. CPAY is ahead.
  26%steadierHow much the price swings42%

Measure	CPAYCorpay	FISVFiserv
Price and returns
Price	$461.87	$63.91
Today	+0.49%	Best in this row: +0.93%
1 month	+16.09%	Best in this row: +40.04%
3 months	+13.72%	Best in this row: +21.23%
This year	Best in this row: +53.51%	−4.87%
1 year	Best in this row: +58.93%	−0.56%
5 years	Best in this row: +93.25%	−36.05%
From 52-week high	−0.0%	−8.5%
How much it swings (90 days)	Best in this row: 26%	42%
Valuation
Market value	$25.7B	$29.7B
Price vs last year's earnings	23.5×	Best in this row: 9.4×
Price vs next year's expected earnings	14.7×	Best in this row: 8.2×
Price vs earnings, adjusted for growth	Best in this row: 0.58×	0.89×
Price to sales	5.6×	Best in this row: 1.6×
Price vs cash it brings in	21.8×	Best in this row: 10.6×
Company value vs operating profit	12.6×	Best in this row: 8.2×
Growth
Revenue growth, 1 year	Best in this row: +21.2%	−1.7%
Revenue growth a year, last 3 years	Best in this row: +9.7%	+6.1%
Earnings per share growth, last year	Best in this row: +16.4%	+3.8%
Earnings per share growth expected next year	Best in this row: +14.3%	+9.1%
Profitability
Kept from sales after making the product	Best in this row: 80.8%	54.8%
Kept as operating profit	Best in this row: 49.8%	19.2%
Kept as final profit	Best in this row: 23.5%	−18.9%
Kept as spare cash	Best in this row: 25.5%	15.2%
Profit on shareholders' money	Best in this row: 32.2%	−17.0%
Profit on all money put in	Best in this row: 15.9%	7.8%
Balance sheet
Net cash (cash minus debt)	Best in this row: −$8.26B	−$26.7B
Debt for each $1 of shareholders' money	3.11×	Best in this row: 1.29×
Short-term assets per $1 of bills due	0.95×	Best in this row: 1.04×
Our readPro
Our call	Buy more	Buy more
Why	Corpay's sales grew 21% over the past year, and the stock rose 10% over the past five trading days after its Nov 4 report beat profit forecasts by 6.1%.	Fiserv rose 40% over the past month, far more than other financial stocks (up 6%).
Where the price sits	in the full report	in the full report
Our overall score (out of 100)	Best in this row: 75	58
Our value score	91	Best in this row: 97
Our growth score	Best in this row: 76	27
Our quality score	Best in this row: 80	70
Our price trend score	58	Best in this row: 59
Earnings and analysts
Analyst consensus	Buy	Hold
To average analyst target	Best in this row: +6.9%	−2.8%
Average analyst target	$493.73	$62.10
Analysts rating it a buy	Best in this row: 81%	19%
Buy ratings added, 3 months	Best in this row: +1	−2
Analysts covering	12	26

CPAY: faster sales growth

Our pick of these: Corpay

Buy more82/100

Sales growth +21.2% vs −1.7%

CPAY +21.2%, FISV −1.7%.

CPAY+21.2%

FISV−1.7%

Forward P/E per point of sales growth 0.69 vs no growth

CPAY 0.69, FISV no growth.

CPAY0.69

FISVno growth

+6.9% to the average analyst target, vs −2.8%

CPAY +6.9%, FISV −2.8%.

CPAY+6.9%

FISV−2.8%

• 2ndFISVBuy more18/100Would need faster sales growth, −1.7% vs +21.2%

Prices as of yesterday, 3:59 PM ET. A view, not advice.